Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaccine companies testing efficacy against COVID-19 Omicron variant

11/26/2021 | 07:25pm EST

Pharmaceutical companies announced plans Friday to test their COVID-19 vaccines' efficacy against the newly designated Omicron variant of the virus.

The World Health Organization named the strain, which originated in South Africa, as a "variant of concern" Friday as nations across the globe announced plans to limit travel from several countries on the African continent.

The agency's technical advisory group said it has a large number of mutations that make it "concerning."

Moderna, which is based in Cambridge, Mass., said the new variant includes a "significant potential risk" to natural and vaccine-inducted immunity to COVID-19.

"The company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks," the company said.

Moderna said it's also testing a higher dose of its mRNA vaccine against the Omicron variant, as well as two multi-valent booster candidates that were designed to anticipate mutations. It's also testing an Omicron-specific booster candidate.

"The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant," Moderna CEO Stéphane Bancel said.

Pfizer-BioNTech said they're also investigating its COVID-19 vaccine's efficacy against the new variant and expects to have results in no more than two weeks, CNBC reported. The companies said they can adapt their mRNA vaccine within six weeks and begin shipping out new batches within 100 days if needed.

"These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," the companies said.

Newsweek reported that an escape variant is one that can avoid the protections of existing vaccines.

Johnson & Johnson said it's also testing its single-dose viral vector vaccine.

"We are closely monitoring newly emerging COVID-19 virus strains with variations of the Sars-CoV-2 spike protein and are already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in Southern Africa," Clare Boyle, a J&J spokeswoman, told CNN in a statement.

And AstraZeneca said it and Oxford University's vaccine platform allows for quick adaptations for mutations.

"AstraZeneca is also already conducting research in locations where the variant has been identified, namely in Botswana and Eswatini," the company said.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source International Top News

All news about MODERNA, INC.
07:44aOMICRON-SPECIFIC VACCINE LIKELY TO C : Sharma
AQ
01/14INSIDER SELL : Moderna
MT
01/14Denver International Airport to Host COVID-19 Vaccine Booster Clinics for Employees and..
AQ
01/14Uganda to Destroy 400,000 Covid-19 Vaccines That Are Due to Expire
AQ
01/13Health Care Down Amid Valuation Concerns -- Health Care Roundup
DJ
01/13Today on Wall Street: Time for a new chapter?
01/13EUROPEAN MIDDAY BRIEFING - Stocks Down, Investors -2-
DJ
01/13WHO, EMA Warn Against Repeated COVID-19 Booster Shots
MT
01/13New data finds AstraZeneca booster generates higher antibodies against Omicron
RE
01/13Moderna Expects to Report Vaccine Data for Young Children in March
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 480 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 706 M - -
P/E ratio 2021 7,75x
Yield 2021 -
Capitalization 83 008 M 83 008 M -
EV / Sales 2021 4,19x
EV / Sales 2022 2,97x
Nbr of Employees 1 300
Free-Float -
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 204,73 $
Average target price 273,06 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684
CELLTRION, INC.-13.64%20 026